Publications

 October 31, 2025 - Published

Multisystem Functional Improvement After NAD⁺-Supported Allogeneic Human Mesenchymal Stem Cell Infusion in a Middle-Aged Male with Hypertension, Anxiety, Sleep Deprivation, and Chronic Fatigue: A Case Report

Daryl Joel Dumdum, MD, DFM

Sure Health 360 Research Institute, 

10th Floor Lanang Premier Doctors Hospital Inc, 

Davao City Philippines

Abstract

Background: Allogeneic human mesenchymal stem cells (hMSCs) are increasingly explored for their immunomodulatory, anti-inflammatory, and pro-repair effects in chronic functional syndromes characterized by fatigue, stress dysregulation, metabolic strain, and pain. Adjunctive metabolic optimization using NAD⁺-based infusion therapy and peptide/nutrient support is hypothesized to improve cellular environment and reduce background inflammation before stem cell administration.

Case Presentation: A 45-year-old male presented with moderate generalized anxiety, uncontrolled hypertension, chronic fatigue, musculoskeletal pain, and insomnia. Baseline blood tests showed mild dyslipidemia, elevated ALT (145 U/L), and HbA1c within the normal-pre-diabetic range (5.25%). The patient underwent an 8-week preparatory phase with NAD⁺ infusions (100–250 mg weekly), metabolic boosters, and GLP-1 analogues (Semaglutide and Tirzepatide) to optimize cellular health and reduce inflammation before stem cell therapy.

Intervention: On September 29, 2025, an intravenous infusion of 50 million GMP-certified, placenta-derived allogeneic hMSCs was administered. The patient was pre-treated and maintained on low-dose methylprednisolone (4 mg OD × 14 days) to suppress  inflammation.

Outcomes: Within 8 weeks post-infusion, the patient demonstrated significant clinical improvement: normalization of blood pressure, increased sleep duration (from 4 to 7 hours), enhanced energy, and resolution of pain and panic episodes. ALT decreased from 145.91 U/L to 54 U/L; HbA1c improved from 5.25% to 5.0%.

Conclusion: A staged protocol combining metabolic/mitochondrial support followed by low-dose immunomodulation and IV allogeneic hMSCs was associated with multi-domain improvement in cardiometabolic, hepatic, and neuropsychological parameters.

Keywords: mesenchymal stem cells, NAD⁺ therapy, hypertension, chronic fatigue, anxiety, regenerative medicine, metabolic priming

Introduction

Chronic fatigue, stress-driven sympathetic overactivity, and metabolic strain often coexist in midlife adults, resulting in overlapping syndromes of hypertension, anxiety, and fatigue. Mesenchymal stem cells (MSCs) offer immunomodulatory and regenerative benefits, while NAD⁺ therapy and metabolic optimization create a conducive cellular environment. This case illustrates a patient managed using a staged regenerative protocol combining both approaches.

Case Presentation

A 45-year-old male (BMI 31.3 kg/m²; 5′6″, 88 kg) presented with hypertension (SBP up to 180 mmHg), moderate anxiety (GAD-7), panic attacks, insomnia (~4 hours/night), chronic fatigue, back pain, and dyslipidemia. Baseline ALT was 145.91 U/L, triglycerides 269 mg/dL, HDL 34.8 mg/dL, HbA1c 5.25%. He was started on an 8-week NAD⁺-based metabolic and detoxification regimen before stem cell infusion.

Table 1 Timeline of Interventions and Outcome 

Table 2 Laboratory Results before and after priming

 Discussion

This case demonstrates the successful application of a comprehensive regenerative approach integrating NAD⁺ therapy, antioxidant support, GLP-1/GIP analogues, and IV allogeneic mesenchymal stem cells. The 8-week priming phase improved metabolic, hepatic, and psychological domains prior to stem cell infusion. ALT reduction (>60%), better HbA1c, and BP normalization indicate systemic improvement. The hMSC infusion likely exerted paracrine anti-inflammatory and neurotrophic effects contributing to pain resolution, improved sleep, and cognitive clarity. This case supports the feasibility and safety of a staged metabolic-regenerative strategy for complex, multi-system dysfunctions commonly seen in midlife adults.

Conclusion

A staged regenerative program involving NAD⁺-based metabolic optimization, low-dose immunomodulation, and IV allogeneic hMSCs led to marked multi-system improvements without adverse events. Larger, ethics-approved series are warranted to confirm these findings.

Informed Consent

Written informed consent for treatment and for publication of anonymized data was obtained from the patient.

References

1.   Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22.

2.   Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplantation. 2016;25(5):829–848.

3.  Katsyuba E, Auwerx J. Modulating NAD⁺ metabolism, from bench to bedside. EMBO Journal. 2017;36(18):2670–2683.

4.  Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213.

5.   Kim J, Yang G, Kim Y, et al. Effects of L-carnitine on energy metabolism and oxidative stress in chronic fatigue. Nutrients. 2020;12(5):1352.

6.   Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1 receptor agonists. Cell Metabolism. 2018;27(4):740–751.

7.   Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.

8.    Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315–317.

9.    Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Immunology Letters. 2015;168(2):217–221.

10.  Levy M, et al. Low-dose corticosteroids in the management of inflammation: mechanisms and clinical relevance. Frontiers in Immunology. 2022;13:857479.

11.  Sharma P, et al. Stem cell therapy for chronic liver disease: current status and future perspectives. World Journal of Gastroenterology. 2020;26(37):5673–5691.

12.  Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2–mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease. 2020;11(2):216–228.

ANNEXES